Argos Therapeutics Inc.: Argos Therapeutics to Hold Third Quarter 2014 Financial Results Conference Call on Thursday, November 13, 2014

Tickers: ARGS
DURHAM, N.C., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its ArcelisĀ® technology platform, today announced that the Company's third quarter 2014 financial results will be released after market close on Thursday, November 13, 2014. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions.

To participate by telephone, please dial (855) 433-0930 (Domestic) or (484) 756-4271 (International). The conference ID number is 26117832. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.argostherapeutics.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its ArcelisĀ® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The Company is also developing a second ArcelisĀ®-based product candidate, AGS-004, for the treatment of HIV, currently being evaluated in a phase 2 clinical trial in combination with a latency reversing drug for HIV eradication in adult patients.Argos Therapeutics, visit www.argostherapeutics.com.

CONTACT: Media:

         Jen Ringler

         Berry & Company Public Relations

         jringler@berrypr.com

         (212) 253-8881



         Investors:

         Angeli Kolhatkar

         Burns McClellan

         akolhatkar@burnsmc.com

         (212) 213-0006
Source: Argos Therapeutics, Inc.

News Provided by Acquire Media

distributed by

This noodl was issued by Argos Therapeutics Inc. and was initially posted at www.argostherapeutics.com. It was distributed, unedited and unaltered, by noodls on 2014-11-06 14:09:26 UTC. The issuer is solely responsible for the accuracy of the information contained therein.